HANSOH PHARMA (03692) announced that its innovative drug Ameile® (Almonertinib Mesylate Tablets) has obtained a drug registration certificate issued by China's National Medical Products Administration (NMPA). The approval adds a new indication for "Ameile® in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations." This marks the fifth approved indication for Ameile®.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments